TITLE

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

PUB. DATE
January 2008
SOURCE
BMC Genetics;2008, Vol. 9, p342
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
43750147

 

Related Articles

  • Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Staedler, Davide; Idrizi, Elita; Kenzaoui, Blanka; Juillerat-Jeanneret, Lucienne // Cancer Chemotherapy & Pharmacology;Nov2011, Vol. 68 Issue 5, p1161 

    Purpose: Doxorubicin is a first-line chemotherapeutic for breast cancer; however, it is associated with severe side effects to non-tumoral tissues. Thus, it is necessary to develop new therapeutic combinations to improve doxorubicin effects at lower concentration of the drug associated with...

  • Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Yoshihiko Ichikawa; Ghanefar, Mohsen; Bayeva, Marina; Rongxue Wu; Khechaduri, Arineh; Prasad, Sathyamangla V. Naga; Mutharasan, R. Kannan; Naik, Tejaswitha Jairaj; Ardehali, Hossein // Journal of Clinical Investigation;Feb2014, Vol. 124 Issue 2, p617 

    Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential...

  • Doxorubicin: The Good, the Bad and the Ugly Effect. Carvalho, Cristina; Santos, Renato X.; Cardoso, Susana; Correia, Sónia; Oliveira, Paulo J.; Santos, Maria S.; Moreira, Paula I. // Current Medicinal Chemistry;Sep2009, Vol. 16 Issue 25, p3267 

    The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body...

  • Activation of PI3K-Akt through taurine is critical for propofol to protect rat cardiomyocytes from doxorubicin-induced toxicity. Sun, Xuechao; Gu, Jing; Chi, Meng; Li, Mingming; Lei, Shi; Wang, Guonian // Canadian Journal of Physiology & Pharmacology;Feb2014, Vol. 92 Issue 2, p155 

    Myocardial toxicity is one of the major side effects of many chemotherapeutics. It has been shown that propofol can ameliorate the cardiotoxicity of chemotherapeutic agents. In this study, we intend to investigate the role of the PI3K-Akt-Bad signaling pathway in propofol relief of...

  • The Role of Milk Thistle Extract in Breast Carcinoma Cell Line (MCF-7) Apoptosis with Doxorubici. Rastegar, Hussein; Ashtiani, Hamidreza Ahmadi; Anjarani, Soghra; Bokaee, Saeed; Khaki, Arash; Javadi, Leila // Acta Medica Iranica;2013, Vol. 51 Issue 9, p591 

    Breast cancer is the most commonly diagnosed invasive malignancy and first leading cause of cancer-related deaths in Iranian women. Based on silymarin's unique characteristics, its application in chemotherapy combined with doxorubicin can be effective to enhance the efficacy together with a...

  • Attenuation of Doxorubicin-Induced Cardiotoxicity by mdivi-1: A Mitochondrial Division/Mitophagy Inhibitor. Gharanei, Mayel; Hussain, Afthab; Janneh, Omar; Maddock, Helen // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Doxorubicin is one of the most effective anti-cancer agents. However, its use is associated with adverse cardiac effects, including cardiomyopathy and progressive heart failure. Given the multiple beneficial effects of the mitochondrial division inhibitor (mdivi-1) in a variety of pathological...

  • The Protective Effect of Royal jelly Against Doxorubicin-induced Renal Oxidative Stress, Histopathological and Immunohistochemiacal Alterations in Ehrlich Ascites Tumor Bearing Mice. El-Kott, Attalla F.; Omar, Nahed A.; Kamal El-Hawary, Hwayda; Mansy, Seham E. // Egyptian Academic Journal of Biological Sciences. D, Histology &;2014, Vol. 5 Issue 1, p9 

    In the present study, we investigated the potential protective effects of royal jelly against doxorubicin-induced nephrotoxicity in Ehrlich ascites tumor bearing mice. Adult male albino mice were randomly divided into eight groups: the control, royal jelly, doxorubicin, and royal jelly plus...

  • Bio Focus: Targeted drug delivery, again and again. Bawazer, Lukmaan A. // MRS Bulletin;Nov2014, Vol. 39 Issue 11, p932 

    The article offers information on the use of biomaterials research for the development of improved strategies in delivering therapeutic drugs to injury- and disease-affected tissues. Topics include the improved targeted drug delivery, the reduction of the side effects of chemotherapy, and the...

  • The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Swift, Lonnie P.; Cutts, Suzanne M.; Nudelman, Abraham; Levovich, Inessa; Rephaeli, Ada; Phillips, Don R. // Cancer Chemotherapy & Pharmacology;Apr2008, Vol. 61 Issue 5, p739 

    The importance of understanding the mechanism of action of anticancer agents is sometimes overlooked in the pursuit of new and therapeutically advantageous compounds. Doxorubicin has long been identified as an inhibitor of the DNA-decatenating enzyme topoisomerase II, this being believed to be...

  • Protease-catalyzed synthesis of the tripeptide CCK26–28, a fragment of CCK-8. R. Joshi; H. Eckstein // Amino Acids;Jul2007, Vol. 33 Issue 1, p91 

    Summary.  Two enzymatically synthetic strategies of the tripeptide derivative PhAc-Asp(OMe)-Tyr-Met-OAl are reported. The second strategy gains the advantage of more economical starting materials, less reaction steps and a higher overall isolated yield of this tripeptide fragment...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics